Psychological effects of psychedelics in adolescents.
Nadhrah Izmi, Robin Lester Carhart-Harris, Hannes Kettner
Front Child Adolesc Psychiatry June 7, 2024 DOI: 10.3389/frcha.2024.1364617 via PubMed Central
Summary
AI-generated from the abstractAdolescents aged 16–24 who self-initiated a psychedelic experience showed significant improvements in psychological well-being four weeks later, with a clinically meaningful average increase of 3.3 points on the Warwick-Edinburgh Mental Wellbeing Scale—similar to changes seen in adults aged 25 and older. However, adolescents reported more challenging acute effects and ego-dissolution, and a higher prevalence of visual symptoms resembling hallucinogen persisting perceptual disorder (73.5% vs. 34.2% in adults), though only one adolescent found these distressing. These findings suggest psychedelic interventions could benefit adolescents but require special attention to risks and treatment design.
Study at a glance
| Characteristics | Observational cohort Peer reviewed |
|---|---|
| Sample size | 1,089 |
| Population | Adolescents (aged 16–24) and adults (aged 25+) who self-initiated a psychedelic experience |
| Duration | 4-week follow-up |
| Keywords | Mental health Psychedelics Youth treatment Neuroscience Clinical research |
| Citations | 23 |
| Key finding | Psychological well-being significantly improved in adolescents two and four weeks after psychedelic use, with changes statistically indistinguishable from adults, but adolescents reported more challenging experiences, ego-dissolution, and a higher prevalence of HPPD-related visual symptoms. |
Abstract
This study aimed to investigate differences in long-term psychological effects, acute subjective effects, and side effects associated with psychedelic use in adolescents (aged 16–24), compared with adults (aged 25+). Data from two observational online survey cohorts was pooled, involving adolescents (average age 20.4 ± 2.2, N = 435) and adults (average age 36.5 ± 9.7, range = 25–71, N = 654) who self-initiated a psychedelic experience and were tracked via online surveys from a pre-experience baseline to four weeks post-use. Self-reported measures of well-being were collected one week before, and two and four weeks after psychedelic use. Acute subjective drug effects, dosage and contextual variables pertaining to the setting of use were measured on the day after the session. Repeated-measures analyses of covariance, t - and z -tests, as well as exploratory correlational and regression analyses tested differences in psychological changes, acute drug effects, and side effects between the two groups. Psychological well-being significantly improved in adolescents two and four weeks following psychedelic use, with a clinically relevant mean change score of 3.3 points (95% CI: 1.1–5.5). on the Warwick-Edinburgh Mental Wellbeing Scale [ F (1.8, 172.9) = 13.41, η 2 G = .04, p < .001], statistically indistinguishable from changes in adults. Acute subjective effects differed between the age groups; adolescents reported significantly higher challenging experiences and ego-dissolution. In adolescents, visual symptoms related to “hallucinogen persisting perceptual disorder” (HPPD) were reported at a higher prevalence than in adults (73.5% vs. 34.2%, p < .001) but were reported as distressing by only one adolescent participant. To our knowledge, this is the first prospective study to examine the psychological effects of psychedelic use specifically in adolescents. Statistically significant improvements in psychological well-being and other domains of mental health were observed, consistent with effects seen previously in adults, providing tentative evidence for the potential utility of psychedelic interventions in adolescents. However, differences in acute subjective effects, specifically the less positive role of ego-dissolution experiences for long-term changes in adolescents, as well as a higher prevalence of HPPD-related symptoms suggest that special considerations might be required when assessing psychedelic treatment design and risks.